Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil

@article{Citrome2016AripiprazoleLI,
  title={Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil},
  author={Leslie Citrome},
  journal={Expert Review of Clinical Pharmacology},
  year={2016},
  volume={9},
  pages={169 - 186}
}
  • L. Citrome
  • Published 1 February 2016
  • Psychology, Medicine
  • Expert Review of Clinical Pharmacology
ABSTRACT Aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) are two different long-acting injectable formulations of aripiprazole. AM 400 mg administered once monthly demonstrated efficacy in an acute, double-blind, placebo-controlled, randomized clinical trial, as well as in a double-blind, placebo-controlled, randomized-withdrawal maintenance study, and in two non-inferiority maintenance studies. AL is a prodrug of aripiprazole and available in 441 mg, 662 mg or 882 mg strengths. AL… 
Aripiprazole Lauroxil: A Review in Schizophrenia
TLDR
Aripiprazole lauroxil LAI therapy was generally well tolerated, with an adverse event profile consistent with that of oral aripipazole (with the exception of injection-site reactions), including a low propensity to cause metabolic disturbances.
Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals.
TLDR
A visual presentation of the relationship between dosage strength of the AL injection, the interval between successive injections, and steady-state aripiprazole plasma concentrations may demonstrate for clinicians how dosage strength and injection interval can be considered in selecting the AL regimen option that best fits the clinical circumstances of the individual patient.
Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
TLDR
There is no available data comparing ALLAI to other antipsychotics, and more head-to-head trials comparing different LAI formulations are needed, but based on the available data, ALLAI is an effective and safe option for treatment of schizophrenia.
Aripiprazole IM depot as an option for the treatment of bipolar disorder
TLDR
Aripiprazole IM depot reduced symptoms of patients with bipolar disorder and a manic episode, increased functioning and quality of life, and protected from recurrence of manic episodes, and proved to be safe/tolerable.
Aripiprazole Lauroxil
TLDR
The PopPK model and model-based simulations were effective means for evaluating aripiprazole lauroxil dosing regimens and management of missed doses and play an important role in determining the use of this long-acting antipsychotic in clinical practice.
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
TLDR
AL and PP were efficacious and well-tolerated for initiating treatment of schizophrenia in the hospital and continuing outpatient treatment and the same AEs were the most common in the PP group.
A safety evaluation of aripiprazole in the treatment of schizophrenia
TLDR
Aripiprazole is a generally well-tolerated third-generation antipsychotic with low rates of motor side effects and metabolic adverse effects that occur commonly with several alternative antipsychotics.
Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study
TLDR
AL demonstrated robust efficacy on CGI-S score, PAN SS subscale scores, PANSS Marder factors, and response rates, and Study limitations included use of a fixed dose for initial oral aripiprazole and fixed monthly AL doses without the option to individualize the oral initiation dosing or injection frequency for efficacy, tolerability, or safety.
...
1
2
3
...

References

SHOWING 1-10 OF 71 REFERENCES
A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
TLDR
Aripiprazole lauroxil demonstrated robust efficacy for treatment of patients experiencing acute exacerbation of schizophrenia, and the improvement in psychotic symptoms was statistically significant and clinically meaningful.
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study
TLDR
Aripiprazole once-monthly 400mg was non-inferior to oral aripipazole, and the reduction in Kaplan–Meier estimated impending relapse rate at week 26 was statistically significant.
Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States
TLDR
AOM consistently provided favorable clinical benefits and should be considered for open access for treatments like AOM, given the heterogeneous nature of schizophrenia and variability in treatment response.
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
TLDR
Aripiprazole-IM-depot significantly delayed time to impending relapse compared with placebo and appears to be a well-tolerated maintenance treatment option for schizophrenia.
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia
TLDR
ARI-OM had a safety and tolerability profile comparable with oral aripiprazole in maintenance treatment of schizophrenia, and there were no unexpected changes in weight or shifts in fasting metabolic parameters across all study phases.
Initiation of aripiprazole once-monthly in patients with schizophrenia
TLDR
Recommendations on how to initiate aripiprazole once-monthly 400 mg (AOM 400), an injectable suspension, in patients with schizophrenia, supported by pharmacokinetic data and based on clinical studies are provided.
Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
TLDR
A post hoc analysis of a 38-week randomized, double-blind, active-controlled, noninferiority study compared the clinical profile of aripiprazole once-monthly 400 mg (AOM 400) in obese and nonobese patients with schizophrenia for ≥3 years with that of AOM 50 mg (subtherapeutic dose).
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole
TLDR
The adverse-event profile of patients receiving aripiprazole once monthly concomitant with oral atypical antipsychotics other than aripIPrazole was consistent with previous reports, suggesting that patients can be safely switched from their existing oral antipsychotic to aripine once monthly without requiring an intermediate stabilization phase with oral aripimrazole.
...
1
2
3
4
5
...